Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.53 |
| ▸ | DUT | P33316 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253635 | 0.93 | HTR2C (0.56) | HTR2AHTR2CMCL1DUTMTNR1A | |
| SCHEMBL6029849 | 0.83 | CDK4 (0.57) | HTR2AHTR2CDUT | |
| SCHEMBL9094075 | 0.83 | DUT (0.51) | HTR2AHTR2CMCL1DUT | |
| SCHEMBL8252214 | 0.81 | DUT (0.49) | MCL1DUT | |
| SCHEMBL6260801 | 0.79 | DUT (0.52) | HTR2AHTR2CMCL1DUT | |
| SCHEMBL9093439 | 0.78 | DUT (0.51) | MCL1DUT | |
| SCHEMBL9092781 | 0.76 | HTR7 (0.49) | HTR2AHTR2CMCL1DUTHTR7 | |
| SCHEMBL4001230 | 0.76 | DUT (0.45) | HTR2AHTR2CMCL1DUTMTNR1A | |
| SCHEMBL22946242 | 0.76 | HTR2C (0.68) | HTR2AHTR2CMCL1MTNR1AMTNR1B | |
| SCHEMBL9093674 | 0.75 | DUT (0.41) | HTR2AHTR2CMCL1DUTMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | HTR2A 3584/4885HTR2C 2689/4885MCL1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.